Rigel Pharmaceuticals | RIGL - Bruttoergebnis Vom Umsatz





Bruttoergebnis Vom Umsatz Veränderung Datum
Agenus USD 34.2M 4.61M 2025-12
Amgen USD 6.89B 415M 2025-12
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
AstraZeneca USD 12.61B 225M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Celldex Therapeutics USD 121K 609K 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Intrexon USD -297K 167K 2024-06
Ionis Pharmaceuticals USD 243M 48M 2026-03
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
Ligand Pharmaceuticals USD 48.45M 8.22M 2026-03
MacroGenics USD 11.24M 19.87M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
Veracyte USD 101.16M 814K 2026-03